ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
Dow Jones
38.798,99
-0,22%
Euro vs US Dollar
1,0804
-0,12%
Bitcoin
69.366,00
0,05%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Medicenna Therapeutics Corporation (MDNA)

  7. Medicenna Therapeutics Corporation (MDNA) News

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MDNA
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202422h29Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MDNAMedicenna Therapeutics Corporation
14/05/202421h42Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MDNAMedicenna Therapeutics Corporation
13/05/202420h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
30/04/202421h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
26/04/202421h28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
25/04/202420h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
22/04/202422h40Edgar (US Regulatory)Form AW - Amendment Withdrawal RequestNASDAQ:MDNAMedicenna Therapeutics Corporation
16/04/202423h05Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MDNAMedicenna Therapeutics Corporation
16/04/202423h05Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:MDNAMedicenna Therapeutics Corporation
16/04/202423h04Edgar (US Regulatory)Form F-10POS - Post-effective amendment to a F-10EF registrationNASDAQ:MDNAMedicenna Therapeutics Corporation
09/04/202420h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
04/04/202420h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
14/02/202413h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
24/01/202422h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
09/01/202416h33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
05/01/202415h06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
22/12/202320h13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
09/11/202314h56GlobeNewswire Inc.Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingNASDAQ:MDNAMedicenna Therapeutics Corporation
08/11/202316h29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
06/11/202313h00GlobeNewswire Inc.Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
03/11/202317h00GlobeNewswire Inc.Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
27/10/202313h55GlobeNewswire Inc.Medicenna Announces Nasdaq Delisting and Cutback of Management TeamNASDAQ:MDNAMedicenna Therapeutics Corporation
25/10/202321h51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
25/10/202313h00GlobeNewswire Inc.Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsNASDAQ:MDNAMedicenna Therapeutics Corporation
24/10/202313h18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
24/10/202313h15GlobeNewswire Inc.Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
10/10/202314h57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
10/10/202313h07GlobeNewswire Inc.Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerNASDAQ:MDNAMedicenna Therapeutics Corporation
03/10/202323h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
03/10/202313h00GlobeNewswire Inc.Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapyNASDAQ:MDNAMedicenna Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:MDNA

Kürzlich von Ihnen besucht

CCOM
US100
US Tech 100
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
USOTC
BASFY
BASF (QX)
FX
EURJPY
Euro vs Yen
NASDAQ
GOOGL
Alphabet
USOTC
BNPQY
BNP Paribas (QX)
TG
BAYN
Bayer
CCOM
SILVER
SILVER
USOTC
ADDYY
Adidas (QX)
NYSE
DIS
Walt Disney
NYSE
NKE
Nike
PM
XAUUSD
Gold vs US Dollar
AMEX
XLF
Financial Select Sector
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten